Currently, lowering the concentration of the apoB-containing lipoproteins and their remnants either by dietary or pharmacological means is the mainstream approach to combat atherosclerosis both in the primary and secondary prevention settings, while the anti-inflammatory therapies serve as adjunct therapies in the setting of secondary prevention strategies. This evidence concerns the gene APOB and atherosclerosis.